查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1750872

CAR-T细胞治疗市场规模、份额、趋势分析报告：按产品、适应症、最终用途、地区、细分市场预测，2025-2030年

CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region and Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

CAR-T细胞治疗市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球 CAR-T 细胞疗法市场规模预计到 2030 年将达到 159.7 亿美元，2025 年至 2030 年的复合年增长率为 22.2%。

CAR-T细胞疗法透过利用患者的免疫系统杀死癌细胞，为淋巴瘤、多发性骨髓瘤和白血病等血癌的治疗带来了模式转移。新兴国家中，多发性骨髓瘤等癌症类型的发生率不断上升，推动市场的发展。强而有力的监管支持，例如产品核可和集中的药物研发管线，也进一步增强了该产业的发展。例如，根据美国国家医学图书馆2023年4月发布的报告，全球约有310项与CAR-T细胞相关的研究正在进行，涵盖早期I期、I期和II期。

为了涵盖全球治疗，各公司正在建立策略联盟并进行地理扩张。因此，各公司正在采取策略，在尚未找到血癌潜在治疗方法和治疗方案的国家扩大地域覆盖范围。例如，2022年8月31日，吉利德旗下的医疗公司Kite宣布将其CAR-T细胞疗法扩展到沙乌地阿拉伯、巴西和新加坡。该公司报告称，新加坡的非何杰金氏淋巴瘤(NHL)发生率超过1,000例，而沙乌地阿拉伯约有1,700例确诊病例。同样，巴西每年约有12,000例非何杰金氏淋巴瘤病例。

COVID-19疫情为患者实施CAR-T细胞疗法带来了挑战，尤其是在疫情初期，许多医院和诊所都挤满了COVID-19患者。许多医院不得不推迟或停止包括CAR-T细胞疗法在内的选择性治疗，以节省资源用于COVID-19患者。此外，由于CAR-T细胞疗法存在严重的副作用，例如细胞激素释放症候群（CRS），可能导致发烧、低血压和器官损伤，这些症状与COVID-19类似，因此治疗也存在问题。

新兴国家的医院和癌症治疗中心越来越多地采用CAR-T细胞疗法。这些中心透过经济高效且省时的癌症治疗，推动了市场的整体成长。例如，2022年8月，墨西哥癌症治疗中心免疫疗法研究所 (Immunotherapy Institute) 开始运营，为美国和加拿大的患者提供CAR-T细胞疗法。同样，在以色列，由于整个治疗过程都在医院内部完成，治疗大约可在10天内完成，从而显着节省了成本。

新兴国家缺乏熟练的专业人员以及高成本仍然是市场成长的挑战。然而，随着人们对技术先进的CAR-T细胞疗法的认知度不断提高以及核准，预计将缓解这些挑战，并在预测期内促进市场成长。根据美国癌症治疗中心的数据，截至2023年，美国FDA已核准六种CAR-T细胞疗法用于治疗血液系统癌症。

CAR-T细胞治疗市场报告重点

  • 根据产品情况，Yescarta（axicabtagene ciloleucel）在 2024 年占据了 50.0% 的市场份额。 Yescarta 的高吸收率归因于其良好的性能和復发性 B 细胞大淋巴瘤成人患者的生存率提高。
  • 按适应症划分，淋巴瘤在2024年占据了CAR-T细胞疗法市场的最大份额。该领域的高市场渗透率归因于该疾病在全球范围内的高发病率。此外，市场参与者对消除CD-19抗原产品的强烈关注也是推动其成长的因素。
  • 根据最终用途，医院部门在 2024 年占据 CAR-T 细胞治疗产业的最大份额。此外，由于医院实验室加快了这一进程，它们正在获得很高的份额。
  • 2024 年，北美占最大份额，为 62.1%。份额较大的主要原因是患者数量庞大，由于核准速度快、医疗保险覆盖范围广，整体上可以获得常见但复杂的医疗保健。

目录

第一章调查方法与范围

第二章执行摘要

3. CAR-T细胞疗法市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • CAR-T细胞疗法市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 CAR-T细胞疗法市场：依产品进行评估与趋势分析

  • 产品细分仪表板
  • CAR-T细胞疗法市场：产品差异分析
  • 2018-2030年全球CAR-T细胞治疗市场规模及产品趋势分析
  • Abecma（Idecabtagemic 双透明细胞）
  • Breyanzi（lysocabtagene malareucel）
  • Carvykti（Silta Cavtagene Autoreucel）
  • Kymriah（Tisagenleclerc）
  • Tecartus（Brexucabtagene Autoreucel）
  • Yescarta（Axicocabtagenesis Siloreucel）
  • 其他的

第五章：CAR-T细胞疗法市场：按适应症的估计和趋势分析

  • 疾病适应症细分仪表板
  • CAR-T细胞治疗市场：适应症差异分析
  • 2018-2030年全球CAR-T细胞治疗市场规模及趋势分析（依适应症）
  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 其他的

第六章 CAR-T细胞治疗市场：依最终用途的估计和趋势分析

  • 产品细分仪表板
  • CAR-T细胞疗法市场：最终用途差异分析
  • 2018-2030年全球CAR-T细胞治疗市场规模及趋势分析（依最终用途）
  • 医院
  • 癌症治疗中心

第七章 CAR-T细胞治疗市场：区域、估计和趋势分析

  • 区域市场仪表板
  • 2024 年及 2030 年区域市场占有率分析
  • CAR-T细胞治疗市场（按地区）
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
  • 亚太地区
    • 日本
    • 中国
  • 其他国家

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key Company Heat Map Analysis, 2024
  • 公司简介
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • bluebird bio, Inc.
    • Merck &Co., Inc.
    • Sangamo Therapeutics
    • Sorrento Therapeutics, Inc.
    • GSK plc.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Growth & Trends:

The global CAR T-cell therapy market size is estimated to reach USD 15.97 billion by 2030, expanding at a CAGR of 22.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights:

  • By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 50.0% in 2024. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
  • The lymphoma segment held the largest CAR T-cell therapy market share in 2024. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
  • By end-use, the hospital segment held the largest share of CAR T-cell therapy industry in 2024 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
  • North America accounted for the largest share of 62.1% in 2024. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Indication
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Disease indication Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. CAR T-cell Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. CAR T-cell Therapy Market Analysis tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. CAR T-cell Therapy Market: Product Movement Analysis
  • 4.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
  • 4.4. Abecma (idecabtagene vicleucel)
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Breyanzi (lisocabtagene maraleucel)
    • 4.5.1. ket Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Carvykti (ciltacabtagene autoleucel)
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Kymriah (tisagenlecleucel)
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Tecartus (brexucabtagene autoleucel)
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.9. Yescarta (axicabtagene ciloleucel)
    • 4.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

  • 5.1. Disease Indication Segment Dashboard
  • 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
  • 5.3. Global CAR T-cell Therapy Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
  • 5.4. Leukemia
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Lymphoma
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Multiple Myeloma
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. CAR T-cell Therapy Market: End Use Estimates & Trend Analysis

  • 6.1. Product Segment Dashboard
  • 6.2. CAR T-cell Therapy Market: End-use Movement Analysis
  • 6.3. Global CAR T-cell Therapy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Cancer Treatment Centers
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. CAR T-cell Therapy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous Bioprocessing Market By Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key Country Dynamics
      • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.1.3. Competitive Scenario
      • 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Germany
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.1.3. Competitive Scenario
      • 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.1.3. Competitive Scenario
      • 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7. Rest of World
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.7.1.3. Competitive Scenario
      • 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key Company Heat Map Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. bluebird bio, Inc.
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Company Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sangamo Therapeutics
      • 8.4.8.1. Company Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Sorrento Therapeutics, Inc.
      • 8.4.9.1. Company Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. GSK plc.
      • 8.4.10.1. Company Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 5 North America CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 6 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 7 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 10 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 11 Canada CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15 Europe CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 17 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 18 Germany CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 20 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 21 UK CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 27 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 28 Japan CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 29 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 30 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 31 China CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Rest of World CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 33 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 34 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 35 Rest of World CAR T-cell therapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 CAR T-cell therapy market: Market outlook
  • Fig. 10 CAR T-cell therapy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 CAR T-cell therapy market driver impact
  • Fig. 16 CAR T-cell therapy market restraint impact
  • Fig. 17 CAR T-cell therapy market strategic initiatives analysis
  • Fig. 18 CAR T-cell therapy market: Product movement analysis
  • Fig. 19 CAR T-cell therapy market: Product outlook and key takeaways
  • Fig. 20 Abecma (idecabtagene vicleucel) market estimates and forecast, 2018 - 2030
  • Fig. 21 Breyanzi (lisocabtagene maraleucel) market estimates and forecast, 2018 - 2030
  • Fig. 22 Carvykti (ciltacabtagene autoleucel) market estimates and forecast, 2018 - 2030
  • Fig. 23 Kymriah (tisagenlecleucel) market estimates and forecast, 2018 - 2030
  • Fig. 24 Tecartus (brexucabtagene autoleucel) market estimates and forecast, 2018 - 2030
  • Fig. 25 Yescarta (axicabtagene ciloleucel) market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 CAR T-cell therapy market: Disease indication movement analysis
  • Fig. 28 CAR T-cell therapy market: Disease indication outlook and key takeaways
  • Fig. 29 Leukemia market estimates and forecasts, 2018 - 2030
  • Fig. 30 Lymphoma market estimates and forecasts,2018 - 2030
  • Fig. 31 Multiple Myeloma market estimates and forecasts, 2018 - 2030
  • Fig. 32 Other market estimates and forecasts, 2018 - 2030
  • Fig. 33 CAR T-cell therapy market: End use movement analysis
  • Fig. 34 CAR T-cell therapy market: End use outlook and key takeaways
  • Fig. 35 Hospitals CAR T-cell therapy market estimates and forecast, 2018 - 2030
  • Fig. 36 Cancer Treatment Centers CAR T-cell therapy estimates and forecast, 2018 - 2030
  • Fig. 37 Global CAR T-cell therapy market: Regional movement analysis
  • Fig. 38 Global CAR T-cell therapy market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 42 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030
  • Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 46 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 47 China market estimates and forecasts, 2018 - 2030
  • Fig. 48 Rest of World market estimates and forecasts, 2018 - 2030